Advertisement

Topics

Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)

2014-08-27 03:18:33 | BioPortfolio

Summary

The purpose of this study is to determine safety and tolerability of the treatment with lithium in Spinocerebellar Ataxia 2. Moreover, clinical symptoms, neuronal loss, quality of life and depressive symptoms, will be considered to further investigate the effect of lithium therapy.

Description

Patients will be progressively enrolled in the study and undergo a screening visit to test for inclusion/exclusion criteria. Patients will then be randomized to receive either Lithium carbonate or placebo. Patients will visit study center at 2, 4, 8, 12, 24, 36 and 48 weeks, for endpoint and laboratory assessments.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Spinocerebellar Ataxia 2

Intervention

LITHIUM CARBONATE

Location

Dipartimento di Scienze Neurologiche
Napoli
Italy
80131

Status

Recruiting

Source

Federico II University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:18:33-0400

Clinical Trials [272 Associated Clinical Trials listed on BioPortfolio]

Functional and Structural Imaging and Motor Control in Spinocerebellar Ataxia

The purpose of this research study is to investigate how the brain and motor behavior changes both in individuals with spinocerebellar ataxia and healthy individuals, and to assess whether...

Lithium Treatment for Patients With Spinocerebellar Ataxia Type I

This study will evaluate the side effects and tolerability of the drug lithium in patients with spinocerebellar ataxia type I (SCA1) an inherited disorder caused by loss of nerve cells in ...

Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia

The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in addition, explo...

Trial in Adult Subjects With Spinocerebellar Ataxia

The purpose of this study is to compare the efficacy of BHV-4157 versus placebo on ataxia symptoms in subjects with spinocerebellar ataxia (SCA).

Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)

ATRIL is a multi-centric, double-blind randomized, two-arm controlled study. 42 SpinoCerebellar Ataxia type 2 (SCA2) patients, both gender, at least 18 years of age will be included. ...

PubMed Articles [876 Associated PubMed Articles listed on BioPortfolio]

Why do so many genetic insults lead to Purkinje Cell degeneration and spinocerebellar ataxia?

The genetically heterozygous spinocerebellar ataxias are all characterized by cerebellar atrophy and pervasive Purkinje Cell degeneration. Up to date, more than 35 functionally diverse spinocerebellar...

Bidirectional Connections between Depression and Ataxia Severity in Spinocerebellar Ataxia Type 3 Patients.

Spinocerebellar ataxia type 3 (SCA3), which is the most common subtype of SCA worldwide, exhibits common neuropsychological symptoms such as depression. However, the contribution of depression to the ...

Impact of disease duration on functional status of patients with spinocerebellar ataxia type 2.

To correlate disease duration in spinocerebellar ataxia type 2 (SCA2) with disease severity, balance and functionality.

Oligonucleotide therapy mitigates disease in Spinocerebellar Ataxia Type 3 mice.

Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is the most common dominantly inherited ataxia. Despite advances in understanding this CAG repeat/polyglutamine expansion di...

Clinical Features of Machado-Joseph Disease.

Machado-Joseph disease (MJD) also known as Spinocerebellar ataxia type 3, is a hereditary neurodegenerative disease associated with severe clinical manifestations and premature death. Although rare, i...

Medical and Biotech [MESH] Definitions

A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.

A salt of lithium that has been used experimentally as an immunomodulator.

Inorganic compounds that contain lithium as an integral part of the molecule.

An ataxin that is associated with the survival of cerebellar neurons. Expansion of the ATTCT pentanucleotide in the ATXN10 coding region is associated with SPINOCEREBELLAR ATAXIA 10.

An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight 6.94. Salts of lithium are used in treating BIPOLAR DISORDER.

More From BioPortfolio on "Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Searches Linking to this Trial